Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

[The Onkonet database: taking stock of an Internet-based, multi-centre database on surgical prostate cancer treatment].

Pohle M, Magheli A, Diederichs W, Ecke T, Fischer T, Kempkensteffen C, Knispel H, Lehsnau M, Miller K, Pretzer J, Schostak M, Winter A, Zacharias M, Hinz S.

Aktuelle Urol. 2019 Jun 13. doi: 10.1055/a-0919-3993. [Epub ahead of print] German.

PMID:
31195415
2.

Correction to: Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer.

Ebbing J, Menzel F, Frumento P, Miller K, Ralla B, Fuller TF, Busch J, Collins JW, Adding C, Seifert HH, Ardelt P, Wetterauer C, Westhoff T, Kempkensteffen C.

BMC Nephrol. 2019 Mar 7;20(1):86. doi: 10.1186/s12882-019-1264-7.

3.

Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer.

Ebbing J, Menzel F, Frumento P, Miller K, Ralla B, Fuller TF, Busch J, Collins JW, Adding C, Seifert HH, Ardelt P, Wetterauer C, Westhoff T, Kempkensteffen C.

BMC Nephrol. 2019 Feb 4;20(1):40. doi: 10.1186/s12882-019-1215-3. Erratum in: BMC Nephrol. 2019 Mar 7;20(1):86.

4.

Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer.

Ebbing J, Heckmann RC, Collins JW, Miller K, Erber B, Friedersdorff F, Fuller TF, Busch J, Seifert HH, Ardelt P, Wetterauer C, Hosseini A, Jentzmik F, Kempkensteffen C.

Sci Rep. 2018 May 30;8(1):8360. doi: 10.1038/s41598-018-26089-x.

5.

Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE).

Cash H, Steiner U, Heidenreich A, Klotz T, Albers P, Melchior S, Martus P, Fuller F, Magheli A, Hinz S, Kempkensteffen C, Miller K; PRINCE investigators.

BJU Int. 2018 Nov;122(5):774-782. doi: 10.1111/bju.14239. Epub 2018 May 6.

PMID:
29633515
6.

Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer.

Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, Makowski MR, Brenner W, Prasad V.

J Nucl Med. 2018 Feb;59(2):238-243. doi: 10.2967/jnumed.117.195172. Epub 2017 Aug 3.

7.

The addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsy.

Günzel K, Cash H, Buckendahl J, Königbauer M, Asbach P, Haas M, Neymeyer J, Hinz S, Miller K, Kempkensteffen C.

BMC Urol. 2017 Jan 13;17(1):7. doi: 10.1186/s12894-016-0196-9.

8.

The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter Setting.

Pohle M, Magheli A, Fischer T, Kempkensteffen C, Busch J, Cash H, Miller K, Hinz S.

Adv Ther. 2017 Feb;34(2):576-585. doi: 10.1007/s12325-016-0469-4. Epub 2017 Jan 4.

9.

Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus.

Maxeiner A, Magheli A, Jöhrens K, Kilic E, Braun TL, Kempkensteffen C, Hinz S, Stephan C, Miller K, Busch J.

BJU Int. 2016 Nov;118(5):750-757. doi: 10.1111/bju.13451. Epub 2016 Mar 19.

10.

Prevalence of Late-Onset Hypogonadism in Men with Localized and Metastatic Renal Cell Carcinoma.

Ralla B, Magheli A, Wolff I, Erber B, Goranova I, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Busch J.

Urol Int. 2017;98(2):191-197. doi: 10.1159/000450652. Epub 2016 Oct 13.

PMID:
27732978
11.

Predictive Parameters Identifying Men Eligible for a Sole MRI/Ultrasound Fusion-Guided Targeted Biopsy without an Additional Systematic Biopsy.

Günzel K, Haas M, Maxeiner A, Stephan C, Buckendahl J, Asbach P, Miller K, Kempkensteffen C, Cash H.

Urol Int. 2017;98(1):15-21. doi: 10.1159/000449258. Epub 2016 Sep 13.

PMID:
27618633
12.

Long-Term Donor Outcomes after Pure Laparoscopic versus Open Living Donor Nephrectomy: Focus on Pregnancy Rates, Hypertension and Quality of Life.

Friedersdorff F, Kothmann L, Manus P, Roigas J, Kempkensteffen C, Magheli A, Busch J, Liefeldt L, Giessing M, Deger S, Schostak M, Miller K, Fuller TF.

Urol Int. 2016;97(4):450-456. Epub 2016 Aug 30.

13.

Outcome of Patients after Third and Fourth Kidney Transplantation.

Friedersdorff F, Patabendhi S, Busch J, Kempkensteffen C, Halleck F, Fuller TF, Miller K, Peters R.

Urol Int. 2016;97(4):445-449. Epub 2016 Jun 17.

PMID:
27310597
14.

Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma.

Ralla B, Erber B, Goranova I, Klooker A, Maxeiner A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J.

Urol Int. 2017;98(2):184-190. doi: 10.1159/000444764. Epub 2016 Mar 11.

PMID:
26963286
15.

Dynamics of Urinary Calprotectin after Renal Ischaemia.

Ebbing J, Seibert FS, Pagonas N, Bauer F, Miller K, Kempkensteffen C, Günzel K, Bachmann A, Seifert HH, Rentsch CA, Ardelt P, Wetterauer C, Amico P, Babel N, Westhoff TH.

PLoS One. 2016 Jan 8;11(1):e0146395. doi: 10.1371/journal.pone.0146395. eCollection 2016.

16.

Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis.

Ralla B, Erber B, Goranova I, von der Aue L, Floercken A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J.

World J Urol. 2016 Aug;34(8):1147-54. doi: 10.1007/s00345-015-1740-z. Epub 2015 Dec 16.

PMID:
26676614
17.

Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer.

Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T.

J Urol. 2016 Apr;195(4 Pt 1):1120-5. doi: 10.1016/j.juro.2015.09.084. Epub 2015 Oct 8.

PMID:
26454102
18.

Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.

Cash H, Günzel K, Maxeiner A, Stephan C, Fischer T, Durmus T, Miller K, Asbach P, Haas M, Kempkensteffen C.

BJU Int. 2016 Jul;118(1):35-43. doi: 10.1111/bju.13327. Epub 2015 Oct 20.

19.

The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.

Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, Asbach P, Haas M, Hinz S, Neymeyer J, Miller K, Günzel K, Kempkensteffen C.

World J Urol. 2016 Apr;34(4):525-32. doi: 10.1007/s00345-015-1671-8. Epub 2015 Aug 21.

PMID:
26293117
20.

Optimizing scintigraphic evaluation of split renal function in living kidney donors using the geometric mean method: a preliminary retrospective study.

Weinberger S, Baeder M, Scheurig-Muenkler C, Steffen IG, Magheli A, Miller K, Kempkensteffen C.

J Nephrol. 2016 Jun;29(3):435-441. doi: 10.1007/s40620-015-0223-z. Epub 2015 Aug 19.

PMID:
26286903
21.

Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.

Aziz A, Kempkensteffen C, May M, Lebentrau S, Burger M, Chun FK, Brookman-May S.

Expert Rev Anticancer Ther. 2015 Jun;15(6):649-66. doi: 10.1586/14737140.2015.1038247. Epub 2015 Apr 23. Review.

PMID:
25905802
22.

[Malignant Sertoli cell tumors of the testes].

Günzel K, Wegner H, Cash H, Lohneis P, Kempkensteffen C, Miller K, Hinz S.

Urologe A. 2015 Aug;54(8):1115-7. doi: 10.1007/s00120-015-3814-3. German.

PMID:
25821170
23.

Evaluation of perioperative complications in open and laparoscopic surgery for renal cell cancer with tumor thrombus involvement using the Clavien-Dindo classification.

Ebbing J, Wiebach T, Kempkensteffen C, Miller K, Bachmann A, Günzel K, Rieken M, Friedersdorff F, Baumunk D, Weikert S.

Eur J Surg Oncol. 2015 Jul;41(7):941-52. doi: 10.1016/j.ejso.2015.02.009. Epub 2015 Mar 11.

PMID:
25817982
24.

[Propensity score comparison of the various radical surgical techniques for high-risk prostate cancer].

Busch J, Gonzalgo M, Leva N, Ferrari M, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Magheli A.

Aktuelle Urol. 2015 Jan;46(1):45-51. doi: 10.1055/s-0034-1395562. Epub 2014 Dec 19. German.

PMID:
25526221
25.

Matched comparison of robot-assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients.

Busch J, Gonzalgo ML, Leva N, Ferrari M, Cash H, Kempkensteffen C, Hinz S, Miller K, Magheli A.

World J Urol. 2015 Mar;33(3):397-402. doi: 10.1007/s00345-014-1326-1. Epub 2014 May 23.

PMID:
24853030
26.

An epigenetic screen unmasks metallothioneins as putative contributors to renal cell carcinogenesis.

Alkamal I, Ikromov O, Tölle A, Fuller TF, Magheli A, Miller K, Krause H, Kempkensteffen C.

Urol Int. 2015;94(1):99-110. doi: 10.1159/000357282. Epub 2014 Mar 20.

PMID:
24662736
27.

Optimizing evaluation of split renal function in a living kidney donor using scintigraphy and calculation of the geometric mean: a case report.

Weinberger S, Bäder M, Scheurig-Münkler C, Hinz S, Neymeyer J, Miller K, Kempkensteffen C.

Case Rep Nephrol Urol. 2014 Jan 10;4(1):1-4. doi: 10.1159/000358007. eCollection 2014 Jan.

28.

Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.

Ebbing J, Mathia S, Seibert FS, Pagonas N, Bauer F, Erber B, Günzel K, Kilic E, Kempkensteffen C, Miller K, Bachmann A, Rosenberger C, Zidek W, Westhoff TH.

World J Urol. 2014 Dec;32(6):1485-92. doi: 10.1007/s00345-013-1227-8. Epub 2013 Dec 31.

PMID:
24378824
29.

Functional Epigenetic Analysis of Prostate Carcinoma: A Role for Seryl-tRNA Synthetase?

Ikromov O, Alkamal I, Magheli A, Ratert N, Sendeski M, Miller K, Krause H, Kempkensteffen C.

J Biomark. 2014;2014:362164. doi: 10.1155/2014/362164. Epub 2014 Mar 27.

30.

Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.

Busch J, Magheli A, Leva N, Ferrari M, Kramer J, Klopf C, Kempkensteffen C, Miller K, Brooks JD, Gonzalgo ML.

BJU Int. 2014 Oct;114(4):517-21. doi: 10.1111/bju.12466. Epub 2014 Jan 22.

31.

Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin.

Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M.

BMC Med Inform Decis Mak. 2013 Aug 5;13:83. doi: 10.1186/1472-6947-13-83.

32.

Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy.

Wotschofsky Z, Busch J, Jung M, Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller K, Kristiansen G, Erbersdobler A, Jung K.

Clin Chim Acta. 2013 Feb 1;416:5-10. doi: 10.1016/j.cca.2012.11.010. Epub 2012 Nov 21.

PMID:
23178446
33.

Long-term outcomes of living donor kidney transplants in pediatric recipients following laparoscopic vs. open donor nephrectomy.

Chaykovska L, Deger S, Roigas J, Lenz A, Lioudmer P, Kothmann LT, Friedersdorff F, Müller D, Kasper A, Giessing M, Magheli A, Kempkensteffen C, Lingnau A, Fuller TF.

Pediatr Transplant. 2012 Dec;16(8):894-900. doi: 10.1111/petr.12008.

PMID:
23131058
34.

Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.

Busch J, Seidel C, Erber B, Issever AS, Hinz S, Kempkensteffen C, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2013 Jul;64(1):62-70. doi: 10.1016/j.eururo.2012.09.004. Epub 2012 Sep 11.

PMID:
22999519
35.

Outcome of expanded criteria donor kidneys that were transplanted at other Eurotransplant centers after being rejected by our institution.

Friedersdorff F, Roller C, Klein G, Werthemann P, Cash H, Budde K, Slowinski T, Kempkensteffen C, Busch J, Fuller TF, Giessing M.

World J Urol. 2013 Aug;31(4):947-52. doi: 10.1007/s00345-012-0929-7. Epub 2012 Aug 18.

PMID:
22903774
36.

Outcomes after laparoscopic living donor nephrectomy: comparison of two laparoscopic surgeons with different levels of expertise.

Friedersdorff F, Werthemann P, Cash H, Kempkensteffen C, Magheli A, Hinz S, Waiser J, Liefeldt L, Miller K, Deger S, Fuller TF.

BJU Int. 2013 Jan;111(1):95-100. doi: 10.1111/j.1464-410X.2012.11348.x. Epub 2012 Jul 3.

37.

Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience.

Busch J, Stephan C, Herold A, Erber B, Kempkensteffen C, Hinz S, Lein M, Weikert S, Miller K, Magheli A.

BJU Int. 2012 Dec;110(11 Pt C):E985-90. doi: 10.1111/j.1464-410X.2012.11279.x. Epub 2012 Jun 6.

38.

Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis.

Busch J, Magheli A, Erber B, Friedersdorff F, Hoffmann I, Kempkensteffen C, Weikert S, Miller K, Schrader M, Hinz S.

BMC Urol. 2012 May 31;12:15. doi: 10.1186/1471-2490-12-15.

39.

Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results.

Busch J, Stephan C, Klutzny A, Hinz S, Kempkensteffen C, Kilic E, Lein M, Weikert S, Miller K, Magheli A.

World J Urol. 2013 Apr;31(2):395-401. doi: 10.1007/s00345-012-0866-5. Epub 2012 May 11.

PMID:
22576695
40.

Selective lymph node dissection for castration-resistant prostate cancer.

Busch J, Hinz S, Kempkensteffen C, Erber B, Klopf C, Weikert S, Miller K, Magheli A.

Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7.

PMID:
22398510
41.

CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele.

Bolbrinker J, Seeberg S, Schostak M, Kempkensteffen C, Baelde H, de Heer E, Kreutz R.

Drug Metab Dispos. 2012 Apr;40(4):639-41. doi: 10.1124/dmd.111.042648. Epub 2012 Jan 3.

PMID:
22214815
42.

Novel options for the treatment of castration-resistant prostate cancer.

Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ.

World J Urol. 2012 Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20. Review.

PMID:
22101903
43.

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21.

PMID:
21802830
44.

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V.

BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295.

45.

Impact of fast-track postoperative care on intestinal function, pain, and length of hospital stay after laparoscopic radical prostatectomy.

Magheli A, Knoll N, Lein M, Hinz S, Kempkensteffen C, Gralla O.

J Endourol. 2011 Jul;25(7):1143-7. doi: 10.1089/end.2011.0020.

PMID:
21740262
46.

[Introduction of interdisciplinary prostate cancer centers based on the recommendations of the German Cancer Society. A cost-benefit analysis 3 years after accreditation].

Weikert S, Baumunk D, Stephan C, Cash H, Jahnke K, Steiner U, Werthemann P, Kempkensteffen C, Magheli A, Hinz S, Jagota A, Reichelt U, Busch J, Klopf C, Miller K, Schostak M.

Urologe A. 2011 Sep;50(9):1083-8. doi: 10.1007/s00120-011-2629-0. German.

PMID:
21728009
47.

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.

Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, Flörcken A, Westermann J, Weinkauf L, Miller K, Keilholz U.

World J Urol. 2013 Aug;31(4):805-9. doi: 10.1007/s00345-011-0676-1. Epub 2011 Apr 22.

PMID:
21512806
48.

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F.

Eur J Cancer. 2010 Nov;46(16):2926-35. doi: 10.1016/j.ejca.2010.07.033. Epub 2010 Aug 24.

PMID:
20797845
49.

Effect of obesity on sex hormone levels, antisperm antibodies, and fertility after vasectomy reversal.

Hinz S, Rais-Bahrami S, Kempkensteffen C, Weiske WH, Miller K, Magheli A.

Urology. 2010 Oct;76(4):851-6. doi: 10.1016/j.urology.2010.01.055.

PMID:
20430424
50.

Robust microRNA stability in degraded RNA preparations from human tissue and cell samples.

Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, Jung K.

Clin Chem. 2010 Jun;56(6):998-1006. doi: 10.1373/clinchem.2009.141580. Epub 2010 Apr 8.

Supplemental Content

Loading ...
Support Center